165 related articles for article (PubMed ID: 33606408)
1. Orbital inflammatory disorders: new knowledge, future challenges.
Kahana A
Curr Opin Ophthalmol; 2021 May; 32(3):255-261. PubMed ID: 33606408
[TBL] [Abstract][Full Text] [Related]
2. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives.
Mishra S; Maurya VK; Kumar S; Ankita ; Kaur A; Saxena SK
Curr Eye Res; 2020 Nov; 45(11):1325-1341. PubMed ID: 32567373
[TBL] [Abstract][Full Text] [Related]
3. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy.
Dik WA; Virakul S; van Steensel L
Exp Eye Res; 2016 Jan; 142():83-91. PubMed ID: 26675405
[TBL] [Abstract][Full Text] [Related]
4. Immunopathogenesis of Graves' ophthalmopathy: the role of the TSH receptor.
Iyer S; Bahn R
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):281-9. PubMed ID: 22632365
[TBL] [Abstract][Full Text] [Related]
5. IGF1 receptor and thyroid-associated ophthalmopathy.
Mohyi M; Smith TJ
J Mol Endocrinol; 2018 Jul; 61(1):T29-T43. PubMed ID: 29273685
[TBL] [Abstract][Full Text] [Related]
6. TSH/IGF1 receptor crosstalk: Mechanism and clinical implications.
Krieger CC; Neumann S; Gershengorn MC
Pharmacol Ther; 2020 May; 209():107502. PubMed ID: 32061922
[TBL] [Abstract][Full Text] [Related]
7. Is There Evidence for IGF1R-Stimulating Abs in Graves' Orbitopathy Pathogenesis?
Krieger CC; Neumann S; Gershengorn MC
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32911689
[TBL] [Abstract][Full Text] [Related]
8. Current Insights into the Pathogenesis of Graves' Ophthalmopathy.
Bahn RS
Horm Metab Res; 2015 Sep; 47(10):773-8. PubMed ID: 26361262
[TBL] [Abstract][Full Text] [Related]
9. TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis.
Krieger CC; Place RF; Bevilacqua C; Marcus-Samuels B; Abel BS; Skarulis MC; Kahaly GJ; Neumann S; Gershengorn MC
J Clin Endocrinol Metab; 2016 Jun; 101(6):2340-7. PubMed ID: 27043163
[TBL] [Abstract][Full Text] [Related]
10. Challenges in Orphan Drug Development: Identification of Effective Therapy for Thyroid-Associated Ophthalmopathy.
Smith TJ
Annu Rev Pharmacol Toxicol; 2019 Jan; 59():129-148. PubMed ID: 30044728
[TBL] [Abstract][Full Text] [Related]
11. Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves' orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation.
Moshkelgosha S; So PW; Deasy N; Diaz-Cano S; Banga JP
Endocrinology; 2013 Sep; 154(9):3008-15. PubMed ID: 23900776
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis of thyroid eye disease: review and update on molecular mechanisms.
Khong JJ; McNab AA; Ebeling PR; Craig JE; Selva D
Br J Ophthalmol; 2016 Jan; 100(1):142-50. PubMed ID: 26567024
[TBL] [Abstract][Full Text] [Related]
13. Comparative Assessment of Female Mouse Model of Graves' Orbitopathy Under Different Environments, Accompanied by Proinflammatory Cytokine and T-Cell Responses to Thyrotropin Hormone Receptor Antigen.
Berchner-Pfannschmidt U; Moshkelgosha S; Diaz-Cano S; Edelmann B; Görtz GE; Horstmann M; Noble A; Hansen W; Eckstein A; Banga JP
Endocrinology; 2016 Apr; 157(4):1673-82. PubMed ID: 26872090
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease.
Ayabe R; Rootman DB; Hwang CJ; Ben-Artzi A; Goldberg R
Ophthalmic Plast Reconstr Surg; 2014; 30(5):415-9. PubMed ID: 24978425
[TBL] [Abstract][Full Text] [Related]
15. Idiopathic sclerosing orbital inflammation and active Graves' orbitopathy.
Detorakis ET; Haniotis V; Mavrikakis I; Drakonaki EE
Ophthalmic Plast Reconstr Surg; 2014; 30(1):77-9. PubMed ID: 24398501
[No Abstract] [Full Text] [Related]
16. Genetic immunization with mouse thyrotrophin hormone receptor plasmid breaks self-tolerance for a murine model of autoimmune thyroid disease and Graves' orbitopathy.
Schlüter A; Horstmann M; Diaz-Cano S; Plöhn S; Stähr K; Mattheis S; Oeverhaus M; Lang S; Flögel U; Berchner-Pfannschmidt U; Eckstein A; Banga JP
Clin Exp Immunol; 2018 Mar; 191(3):255-267. PubMed ID: 29058307
[TBL] [Abstract][Full Text] [Related]
17. Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients.
van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
Thyroid; 2010 May; 20(5):535-44. PubMed ID: 20384487
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of human orbital tissue in Graves' orbitopathy.
Hai YP; Lee ACH; Frommer L; Diana T; Kahaly GJ
J Endocrinol Invest; 2020 Feb; 43(2):123-137. PubMed ID: 31538314
[TBL] [Abstract][Full Text] [Related]
19. [Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?].
Wall JR; Lahooti H
Endokrynol Pol; 2011; 62 Suppl 1():1-7. PubMed ID: 22125104
[TBL] [Abstract][Full Text] [Related]
20. High-Mobility Group Box 1 Is Associated with the Inflammatory Pathogenesis of Graves' Orbitopathy.
Han SY; Choi SH; Shin JS; Lee EJ; Han SH; Yoon JS
Thyroid; 2019 Jun; 29(6):868-878. PubMed ID: 30973094
[No Abstract] [Full Text] [Related]
[Next] [New Search]